A vs. WST: Agilent vs. West Pharmaceutical Services Stock Comparison
How do Agilent (A) and West Pharmaceutical Services (WST) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and West Pharmaceutical Services (WST) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | A | WST |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | West Pharmaceutical Services Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 49.28 billion USD | 27.85 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | November 18, 1999 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | WST |
|---|---|---|
| Total Return (1Y) | 22.92% | 51.68% |
| Total Return (3Y, Annualized) | 19.33% | 7.13% |
| Total Return (5Y, Annualized) | 3.03% | 0.05% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | WST |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 31.45% |
| Beta (5Y) | 1.22 | 1.13 |
| Max Drawdown (5Y) | -38.09% | -59.29% |
| Avg. Volume (3M) | 2.25M | 603.86K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | WST |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | 1.51 |
| Sortino Ratio (1Y) | 0.96 | 2.35 |
Profitability
ROE (TTM)
Both Agilent (A) at 20.97% and West Pharmaceutical Services (WST) at 21.23% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.23%
- Max
- 109.18%
- WST
- 21.23%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Agilent (A) at 19.53% and West Pharmaceutical Services (WST) at 18.81% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.81%
- WST
- 18.81%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Agilent (A) at 25.56% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.37%
- Max
- 83.12%
- WST
- 25.37%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | WST |
|---|---|---|
| ROE (TTM) | 20.97% | 21.23% |
| ROA (TTM) | 8.63% | 11.89% |
| Net Margin (TTM) | 19.53% | 18.81% |
| Operating Margin (TTM) | 25.56% | 25.37% |
| Gross Margin (TTM) | 53.65% | 37.59% |
Growth
Revenue Growth
Both Agilent (A) at 6.73% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Agilent (A) at 3.16% and West Pharmaceutical Services (WST) at 1.49% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | A | WST |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 6.25% |
| Revenue Growth (3Y CAGR) | 0.48% | 2.12% |
| EPS Growth (YoY) | 3.16% | 1.49% |
| EPS Growth (3Y CAGR) | 3.02% | -4.23% |
Financial Strength
Current Ratio (MRQ)
West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- WST
- 2.82
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Agilent (A) at 0.56 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.11
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- WST
- 0.11
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | A | WST |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | 2.82 |
| Debt / Equity (MRQ) | 0.56 | 0.11 |
| Net Debt / EBITDA | 1.15 | -0.16 |
Dividends
Dividend Yield (TTM)
Both Agilent (A) at 0.59% and West Pharmaceutical Services (WST) at 0.22% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.22%
- WST
- 0.22%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Agilent (A) at 19.98% and West Pharmaceutical Services (WST) at 9.88% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88%
- WST
- 9.88%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | WST |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 0.22% |
| Dividend Payout Ratio (TTM) | 19.98% | 9.88% |
Valuation
P/E Ratio (TTM)
Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while West Pharmaceutical Services (WST) at 44.87 sits in the richer quartile — WST needs stronger growth or earnings quality to justify the premium.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.87
- Max
- 85.34
- WST
- 44.87
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Agilent (A) at 6.68 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20
- Max
- 58.18
- Q3
- 25.77
- WST
- 8.20
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both Agilent (A) at 6.69 and West Pharmaceutical Services (WST) at 9.40 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.40
- Max
- 13.53
- WST
- 9.40
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | A | WST |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | 44.87 |
| P/S Ratio (TTM) | 6.68 | 8.20 |
| P/B Ratio (MRQ) | 6.69 | 9.40 |
| Free Cash Flow Yield (TTM) | 2.15% | 1.24% |